Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia.
作者信息
Citrome Leslie
出版信息
Evid Based Ment Health. 2018 Aug;21(3):e12. doi: 10.1136/eb-2017-102825. Epub 2018 Jun 26.
Abstract
摘要
相似文献
1
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia.2型囊泡单胺转运体抑制可有效且耐受地管理迟发性运动障碍。
Evid Based Ment Health. 2018 Aug;21(3):e12. doi: 10.1136/eb-2017-102825. Epub 2018 Jun 26.
2
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.氘代丁苯那嗪用于治疗迟发性运动障碍患者的不自主运动。
Expert Rev Neurother. 2021 Jan;21(1):9-20. doi: 10.1080/14737175.2021.1848548. Epub 2020 Nov 23.
3
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?比较囊泡单胺转运体 2（VMAT2）抑制剂瓦伦扎嗪和右苯丙胺治疗迟发性运动障碍的药理作用机制：一种是否优于另一种？
CNS Spectr. 2018 Aug;23(4):239-247. doi: 10.1017/S1092852918001219.
4
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.用于迟发性运动障碍的VMAT2抑制剂——实践意义
J Pharm Pract. 2019 Aug;32(4):450-457. doi: 10.1177/0897190018756512. Epub 2018 Feb 18.
5
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.迟发性运动障碍：将囊泡单胺转运体 2（VMAT2）抑制剂置于临床视角。
Expert Rev Neurother. 2018 Apr;18(4):323-332. doi: 10.1080/14737175.2018.1455504. Epub 2018 Apr 2.
6
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.用丁苯那嗪或缬苯那嗪治疗迟发性运动障碍：一项系统评价
J Comp Eff Res. 2018 Feb;7(2):135-148. doi: 10.2217/cer-2017-0065. Epub 2017 Oct 2.
7
Deutetrabenazine in the treatment of tardive dyskinesia.丁苯那嗪治疗迟发性运动障碍
Neurodegener Dis Manag. 2019 Apr;9(2):59-71. doi: 10.2217/nmt-2018-0042. Epub 2019 Jan 31.
8
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.Valbenazine 和 deutetrabenazine：用于迟发性运动障碍的囊泡单胺转运体 2 抑制剂。
Am J Health Syst Pharm. 2020 Jan 24;77(3):167-174. doi: 10.1093/ajhp/zxz299.
9
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.氘代丁苯那嗪治疗迟发性运动障碍患者不自主运动的研究（AIM-TD）：一项双盲、随机、安慰剂对照的3期试验。
Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.
10
Valbenazine for the treatment of tardive dyskinesia.苯丁酸钠治疗迟发性运动障碍。
Expert Rev Neurother. 2017 Dec;17(12):1135-1144. doi: 10.1080/14737175.2017.1386556. Epub 2017 Oct 12.
本文引用的文献
1
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.迟发性运动障碍：将囊泡单胺转运体 2（VMAT2）抑制剂置于临床视角。
Expert Rev Neurother. 2018 Apr;18(4):323-332. doi: 10.1080/14737175.2018.1455504. Epub 2018 Apr 2.
2
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.氘代丁苯那嗪治疗迟发性运动障碍患者不自主运动的研究（AIM-TD）：一项双盲、随机、安慰剂对照的3期试验。
Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.
3
Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?用于迟发性运动障碍的氘代丁苯那嗪：对这种新批准的新型药物的疗效和安全性概况的系统评价——治疗所需人数、伤害所需人数以及受益或受害可能性是多少？
Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12.
4
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.氘代丁苯那嗪治疗迟发性运动障碍的随机对照试验：ARM-TD研究。
Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26.
Zotero 插件